FDA-approved antiemetics; direct antitumor research ongoing
Cannabinoids have the longest regulatory history in oncology — dronabinol (synthetic THC) was FDA-approved for chemotherapy-induced nausea in 1985. Beyond antiemetic use, cannabinoids are studied for cancer pain, appetite stimulation, and increasingly for direct antitumor effects. Preclinical evidence for antitumor activity is substantial; clinical evidence remains limited but growing.
Medical Disclaimer: Cannabis does not treat cancer. Always disclose cannabis use to your oncologist — cannabinoids can interact with chemotherapy drugs. Never substitute cannabis for evidence-based cancer treatment.
Cancer and its treatments produce a constellation of symptoms — nausea, pain, anorexia, anxiety, and insomnia — that significantly impair quality of life. Cannabinoids address multiple symptom domains simultaneously, making them attractive adjuncts to conventional oncology care. The antiemetic evidence is strongest: dronabinol (Marinol) and nabilone (Cesamet) are FDA-approved for chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics. CBDA, the raw precursor to CBD, shows 100-1000x greater antiemetic potency than CBD in preclinical models via 5-HT1A agonism. For cancer pain, cannabinoids provide modest analgesia and may reduce opioid requirements. For appetite, dronabinol is FDA-approved for AIDS-related anorexia and is used off-label for cancer cachexia. The most exciting frontier is direct antitumor effects: preclinical studies show cannabinoids induce apoptosis, inhibit angiogenesis, and reduce tumor invasion in multiple cancer cell lines. However, no clinical trial has demonstrated antitumor efficacy in humans, and some studies suggest cannabinoids may promote tumor growth in certain contexts. Clinical trials of cannabinoids as antitumor agents are in early phases.
Evidence summary for cannabinoid-based interventions in Cancer & Oncology.
Mechanism: CB1/CB2 agonism reduces nausea via brainstem and GI tract; stimulates appetite via hypothalamic CB1 receptors
Clinical Status: FDA-approved for CINV and AIDS-related anorexia; used off-label for cancer cachexia
Schedule III controlled substance. Oral capsules (2.5–10mg). Variable bioavailability (10–20%). Slower onset than inhaled cannabis. Approved since 1985 — longest regulatory history of any cannabinoid.
Mechanism: Synthetic THC analogue; CB1/CB2 agonism; more potent and longer-acting than dronabinol
Clinical Status: FDA-approved for CINV; Schedule II controlled substance
More potent than dronabinol. Used when dronabinol is insufficient. Also studied off-label for cancer pain and sleep. Higher psychoactive potency increases adverse effect risk.
Mechanism: Anti-inflammatory, anxiolytic, and potential direct antitumor effects (apoptosis induction, angiogenesis inhibition in preclinical models)
Clinical Status: Limited RCT evidence for cancer symptoms; preclinical antitumor evidence; clinical trials ongoing
Non-psychoactive. May reduce cancer-related anxiety and pain. Preclinical antitumor evidence is promising but has not translated to clinical trials. Drug interactions with chemotherapy agents require monitoring.
Mechanism: 5-HT1A agonism — 100-1000x more potent antiemetic than CBD in preclinical models
Clinical Status: Preclinical only; GW Pharmaceuticals developing stable CBDA derivative (HU-580)
Most potent antiemetic cannabinoid in preclinical models. Instability (converts to CBD) has limited clinical development. CBDA methyl ester (HU-580) is in development.
Peer-reviewed research on cannabinoids and Cancer & Oncology.
Cunningham D, Bradley CJ, Forrest GJ, et al. · British Medical Journal
Nabilone was significantly more effective than prochlorperazine for chemotherapy-induced nausea and vomiting, with 73% of patients preferring nabilone.
View on DOI.orgVelasco G, Sánchez C, Guzmán M · British Journal of Pharmacology
Comprehensive review of preclinical antitumor evidence for cannabinoids, covering apoptosis induction, autophagy, anti-angiogenesis, and anti-metastatic mechanisms across multiple cancer types.
View on DOI.orgGuzmán M, Duarte MJ, Blázquez C, et al. · British Journal of Cancer
First clinical trial of intratumoral THC in glioblastoma. THC was safe and showed antiproliferative activity in 2 of 9 patients. Proof-of-concept for direct antitumor cannabinoid administration.
View on DOI.orgNo. There is no clinical evidence that cannabis cures cancer. Preclinical studies show cannabinoids can kill cancer cells in laboratory settings, but these findings have not translated to clinical antitumor efficacy in human trials. Cannabis should not be used as a substitute for evidence-based cancer treatment.
Yes — dronabinol and nabilone are FDA-approved for chemotherapy-induced nausea and vomiting. They are generally used when first-line antiemetics (5-HT3 antagonists, NK1 antagonists) are insufficient. Inhaled cannabis may also reduce nausea but has not been formally approved.
Yes — CBD inhibits CYP3A4 and CYP2C9 enzymes, which metabolize many chemotherapy drugs. This can increase chemotherapy drug levels and toxicity. THC also inhibits CYP enzymes. Always disclose cannabis use to your oncologist before starting chemotherapy.
Cannabinoids provide modest analgesia for cancer pain and may reduce opioid requirements in some patients. Evidence is less robust than for neuropathic pain. Cannabis is generally considered an adjunct to opioid analgesia in cancer pain management, not a replacement.
